Kardigan Completes Enrollment in Phase 2b Ataciguat Trial for Aortic Stenosis

• Kardigan completed enrollment of 156 participants in its Phase 2b KATALYST-AV trial of ataciguat for aortic stenosis.
• Wide variation in baseline valve calcium prompted extending the primary assessment to Week 48; an internal interim analysis remains at Week 24.
• A real-world analysis of approximately 45,000 patients linked cardiac damage to faster disease progression and worse outcomes.
• Additional trial baseline findings and real-world results will be presented at an investor webcast on November 7, 2026.
• Phase 3 development plans are expected in the first half of 2027, with Week 48 topline results due in the second half.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kardigan Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261106140559) on November 06, 2026, and is solely responsible for the information contained therein.